Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409654774> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2409654774 endingPage "80" @default.
- W2409654774 startingPage "471" @default.
- W2409654774 abstract "A camptothecin-resistant subline of P388 leukemia (P388/CPT) was developed by repeated transplantation of P388 cells in mice treated with therapeutic doses of camptothecin. In mice bearing the resistant tumor, a maximally tolerated dose of camptothecin produced no net reduction in tumor cell burden, in contrast to a 5-log cell kill in the parental P388 (P388/S). The IC50 of camptothecin, as determined by colony formation assays of cultured cells, was 8 times greater for the cloned P388/CPT cell line than for P388/S. P388/CPT cells were not cross-resistant to other antineoplastic agents, including topoisomerase II inhibitors. The type I topoisomerases purified from P388/CPT and P388/S cells were identical with respect to molecular weight, specific activity, in vitro camptothecin sensitivity, and DNA cleavage specificity. Camptothecin induced fewer protein-associated DNA single-strand breaks in the resistant cells than in the wild-type P388 cells. Topoisomerase I mRNA, immunoreactivity, and extractable enzymatic activity were 2-4 times lower for P388/CPT cells than for P388/S cells. As resistance to camptothecin developed, topoisomerase I extractable activity decreased, concomitant with an increase in topoisomerase II extractable activity. Furthermore, the appearance of camptothecin resistance was associated with specific rearrangements of the topoisomerase I gene. These results suggest that development of resistance to inhibitors of topoisomerase I can occur by down-regulation of the target enzyme, thus reducing the production of lethal enzyme-mediated DNA damage. The enhanced topoisomerase II activity in these cells suggests that resistance to camptothecin may be overcome by co-treatment with topoisomerase II inhibitors." @default.
- W2409654774 created "2016-06-24" @default.
- W2409654774 creator A5004812126 @default.
- W2409654774 creator A5013946717 @default.
- W2409654774 creator A5025765869 @default.
- W2409654774 creator A5041417593 @default.
- W2409654774 creator A5041975716 @default.
- W2409654774 creator A5055073284 @default.
- W2409654774 creator A5063171945 @default.
- W2409654774 creator A5065779604 @default.
- W2409654774 date "1990-10-01" @default.
- W2409654774 modified "2023-09-23" @default.
- W2409654774 title "Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content." @default.
- W2409654774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2172765" @default.
- W2409654774 hasPublicationYear "1990" @default.
- W2409654774 type Work @default.
- W2409654774 sameAs 2409654774 @default.
- W2409654774 citedByCount "53" @default.
- W2409654774 countsByYear W24096547742013 @default.
- W2409654774 countsByYear W24096547742016 @default.
- W2409654774 crossrefType "journal-article" @default.
- W2409654774 hasAuthorship W2409654774A5004812126 @default.
- W2409654774 hasAuthorship W2409654774A5013946717 @default.
- W2409654774 hasAuthorship W2409654774A5025765869 @default.
- W2409654774 hasAuthorship W2409654774A5041417593 @default.
- W2409654774 hasAuthorship W2409654774A5041975716 @default.
- W2409654774 hasAuthorship W2409654774A5055073284 @default.
- W2409654774 hasAuthorship W2409654774A5063171945 @default.
- W2409654774 hasAuthorship W2409654774A5065779604 @default.
- W2409654774 hasConcept C147897179 @default.
- W2409654774 hasConcept C153911025 @default.
- W2409654774 hasConcept C181199279 @default.
- W2409654774 hasConcept C202751555 @default.
- W2409654774 hasConcept C2779682216 @default.
- W2409654774 hasConcept C2780500152 @default.
- W2409654774 hasConcept C54355233 @default.
- W2409654774 hasConcept C552990157 @default.
- W2409654774 hasConcept C55493867 @default.
- W2409654774 hasConcept C81885089 @default.
- W2409654774 hasConcept C86803240 @default.
- W2409654774 hasConceptScore W2409654774C147897179 @default.
- W2409654774 hasConceptScore W2409654774C153911025 @default.
- W2409654774 hasConceptScore W2409654774C181199279 @default.
- W2409654774 hasConceptScore W2409654774C202751555 @default.
- W2409654774 hasConceptScore W2409654774C2779682216 @default.
- W2409654774 hasConceptScore W2409654774C2780500152 @default.
- W2409654774 hasConceptScore W2409654774C54355233 @default.
- W2409654774 hasConceptScore W2409654774C552990157 @default.
- W2409654774 hasConceptScore W2409654774C55493867 @default.
- W2409654774 hasConceptScore W2409654774C81885089 @default.
- W2409654774 hasConceptScore W2409654774C86803240 @default.
- W2409654774 hasIssue "4" @default.
- W2409654774 hasLocation W24096547741 @default.
- W2409654774 hasOpenAccess W2409654774 @default.
- W2409654774 hasPrimaryLocation W24096547741 @default.
- W2409654774 hasRelatedWork W1587495423 @default.
- W2409654774 hasRelatedWork W1946967684 @default.
- W2409654774 hasRelatedWork W1983401261 @default.
- W2409654774 hasRelatedWork W2057945316 @default.
- W2409654774 hasRelatedWork W2066828524 @default.
- W2409654774 hasRelatedWork W2118553080 @default.
- W2409654774 hasRelatedWork W2130039633 @default.
- W2409654774 hasRelatedWork W2418245102 @default.
- W2409654774 hasRelatedWork W32442640 @default.
- W2409654774 hasRelatedWork W2011173021 @default.
- W2409654774 hasVolume "38" @default.
- W2409654774 isParatext "false" @default.
- W2409654774 isRetracted "false" @default.
- W2409654774 magId "2409654774" @default.
- W2409654774 workType "article" @default.